Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of concomitant nOPV2 with Sabin OPV in children in Mozambique
PACTR202404654347323Not yet recruiting
- Sponsor
- World Health Organization
- Start
- May 2024
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of nOPV2, monovalent oral polio vaccine type 1 and bivalent oral poliovirus vaccine in poliomyelitis (3 arms), sponsored by World Health Organization. Planned start May 2024; status: not yet recruiting.
02
Drugs
nOPV2monovalent oral polio vaccine type 1bivalent oral poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on PACTR202404654347323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404654347323.